journal article Jun 19, 2025

Sarcopenia and Osteoporosis

Gerontology Vol. 71 No. 8 pp. 649-655 · S. Karger AG
View at Publisher Save 10.1159/000546501
Abstract
Background: Sarcopenia and osteoporosis are common age-related conditions that frequently coexist, forming a syndrome known as osteosarcopenia. Sarcopenia is defined by the progressive loss of muscle mass, strength, and function, while osteoporosis is characterized by reduced bone mineral density and altered bone quality. Together, they significantly increase the risk of falls, fractures, and functional decline in older adults. Summary: Osteosarcopenia arises from shared pathophysiological mechanisms, including chronic low-grade inflammation, oxidative stress, hormonal changes, and nutritional deficiencies. These factors contribute to a cycle of musculoskeletal deterioration. In addition to systemic pathways, local muscle-bone crosstalk mediated by myokines and osteokines plays a critical role. Management requires a comprehensive approach. Nutritional interventions such as adequate protein, calcium, and vitamin D intake, along with anti-inflammatory nutrients like omega-3 fatty acids and polyphenols, support musculoskeletal health. Resistance and weight-bearing exercises are essential to maintain muscle and bone mass. Pharmacological treatments for osteoporosis include bisphosphonates, denosumab, and anabolic agents, while investigational therapies for sarcopenia, such as selective androgen receptor modulators and myostatin inhibitors, offer potential benefits. Key Messages: Sarcopenia and osteoporosis share risk factors and often coexist in older adults. Early diagnosis and integrated treatment strategies are essential. Nutrition, exercise, and pharmacologic interventions can mitigate the burden of osteosarcopenia. A combined approach is more effective than treating each condition separately and may reduce falls and improve quality of life.
Topics

No keywords indexed for this article. Browse by subject →

References
48
[4]
Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly

Emanuela A. Greco, Peter Pietschmann, Silvia Migliaccio

Frontiers in Endocrinology 10.3389/fendo.2019.00255
[5]
Osteoporosis in the European Union: medical management, epidemiology and economic burden

E. Hernlund, A. Svedbom, M. Ivergård et al.

Archives of Osteoporosis 10.1007/s11657-013-0136-1
[6]
Clinician’s Guide to Prevention and Treatment of Osteoporosis

F. Cosman, S. J. de Beur, M. S. LeBoff et al.

Osteoporosis International 10.1007/s00198-014-2794-2
[18]
[20]
Muscle, Bone, and Fat Crosstalk: the Biological Role of Myokines, Osteokines, and Adipokines

Ben Kirk, Jack Feehan, Giovanni Lombardi et al.

Current Osteoporosis Reports 10.1007/s11914-020-00599-y
[29]
Vitamin D3and Calcium to Prevent Hip Fractures in Elderly Women

Marie C. Chapuy, Monique E. Arlot, François Duboeuf et al.

New England Journal of Medicine 10.1056/nejm199212033272305
[43]
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline

Richard Eastell, Clifford J Rosen, Dennis M Black et al.

The Journal of Clinical Endocrinology & Metabo... 10.1210/jc.2019-00221
[44]
A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction

Myung-Rae Cho, Sungho Lee, Sang Jun Song

Journal of Korean Medical Science 10.3346/jkms.2022.37.e146
[48]
Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians

Susan J. Diem, Nancy L. Greer, Roderick MacDonald et al.

Annals of Internal Medicine 10.7326/m19-0830
Metrics
5
Citations
48
References
Details
Published
Jun 19, 2025
Vol/Issue
71(8)
Pages
649-655
License
View
Cite This Article
Edoardo Mocini, Claudia Piciocchi, Giuseppe Defeudis, et al. (2025). Sarcopenia and Osteoporosis. Gerontology, 71(8), 649-655. https://doi.org/10.1159/000546501